Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 23381-23390 Newer>

The Motley Fool May 22, 2007 David Lee Smith	Is Alcoa's Bid for Alcan Backwards? Would Alcan turning the tables and bidding for Alcoa be the preferable direction? Investors should watch this very, very carefully.
The Motley Fool May 22, 2007 Toby Shute	GE Cashes In on Plastic The conglomerate got top dollar for its plastics business. Now, what to do with all that cash? Buybacks keep the market happy, but they may not be the wisest use of capital today.
The Motley Fool May 21, 2007 Rick Aristotle Munarriz	EMI's Cold Play EMI turns to private equity as an exit strategy. Investors, take note.
The Motley Fool May 21, 2007 Rich Smith	My Wrong Turn on Lifeway Kefir maker Lifeway Foods advised that it has landed its first big food service client, U.S. Foodservice. What does Lifeway's announcement mean to investors? Well, that depends.
The Motley Fool May 21, 2007 Ryan Fuhrmann	The Saks Are Packed The retailer's strong sales trends are nothing to sneeze at, but Saks still has work to do to convince investors its high-end ambitions will translate into industry-leading profitability and cash flow growth.
The Motley Fool May 21, 2007 Ryan Fuhrmann	Foolish Forecast: Cracker Barrel Paves a Simpler Road CBRL, the holding company for Cracker Barrel Old Country Stores, is set to report its recent quarterly report. Investors, here is what you can expect to see.
The Motley Fool May 21, 2007 Rick Aristotle Munarriz	3 Stocks That Blew the Market Away Beat the market, and the world will beat a path to your door. Intuit... Focus Media... Rediff.com...
The Motley Fool May 21, 2007 Rich Smith	Foolish Forecast: Checking Turbochef's Pilot Light The oven maker is set to release first-quarter 2007 earnings. Investors, here is what you can expect to see.
The Motley Fool May 21, 2007 Anders Bylund	Foolish Forecast: Buoyant Analog Devices The broad-line semiconductor designer is set to report its most recent quarterly earnings. Investors, here is what you can expect to see.
The Motley Fool May 21, 2007 Brian Lawler	DUSA's Orphan Isn't Unique The pharmaceutical gets "orphan drug" status for its lead compound. Investors, take note.
<Older 23381-23390 Newer> Return to current articles.